Floatz logo

Velpatasvir

Hepatitis C Virus Infection

Peking University People's HospitalSmall moleculePhase 4 / ApprovedActive
A
84/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
76/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Hepatitis C Virus Infection cohort.

Asset / SponsorPhaseRating
Veruprevir
AbbVie
Phase 4A
Daclatasvir
MTI University
Phase 4A
PIBRENTASVIR
AbbVie
Phase 3A
GLECAPREVIR
AbbVie
Phase 3A
OMBITASVIR
AbbVie
Phase 3A

View all 50 →

Same molecule, other indications

Velpatasvir is also rated in:

iatrogenic diseaseDormant
BB
Indicative · Phase 4
69 / 100
View asset →
chronic hepatitis C virus infectionDormant
BB
Indicative · Phase 4
65 / 100
View asset →
chronic hepatitis B virus infectionDormant
BB
Indicative · Phase 4
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →